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Abstract 
We have previously shown that whereas T-cells from normal individuals undergo accumulation of 
p53 and apoptosis when treated with the genotoxic agent Actinomycin D (ActD), those from Ataxia 
Telangiectasia (AT) and Nijmegen Breakage Syndrome (NBS) patients resist ActD-induced 
apoptosis [1]. We have now found similar resistance by the p53-null Jurkat T-cell line and by 
siRNA p53-knockdown normal T-cells. This evidence that ActD initiates a p53-dependent apoptotic 
responce prompted us to look for defective p53 accumulation by AT and NBS T-cells. Surprisingly 
the total p53 level was only slightly reduced compared to normal T cells but its intracellular 
localization was highly defective: p53 was poorly accumulated in the cytosol and nearly 
undetectable in mitochondria. In accordance with the dependence of ActD-induced apoptosis on a 
mitochondrial p53 function, in control T-cells specific inhibition of mitochondrial p53 translocation 
with µ pifithrin reduced apoptosis by 86%, whereas treatment with α pifithrin, which blocks p53-
mediated transcription, had no effect. We also showed that nuclear export is not required for 
mitochondrial p53 translocation. Observation of an altered p53 ubiquitination pattern and Mdm2 
accumulation in ActD-treated AT and NBS T-cells provided a mechanistic link to their defective 
extranuclear p53 localization. 
Our results disclose an undescribed defect in mitochondrial p53 accumulation in AT and NBS T-










1. Introduction  
DNA damage-induced apoptosis and precise DNA repair are critical cellular function, and both are 
needed to prevent cancer [2-6]. Defective apoptosis contributes to mutagenesis, carcinogenesis, and 
the resistance of cancer cells to a variety of therapeutic agents [6]. DNA damage-induced apoptosis 
involves the participation of several factors with both overlapping and distinct functions, that are 
largely mediated by p53) [7, 8]. In conditions of genotoxic stress, the increased abundance of p53 
orchestrates multiple responses that involve both transcription-dependent and transcription-
independent mechanisms [9]. In the nucleus, p53 acts as a transcription factor to induce pro-
apoptotic and/or cell cycle arresting programs by transactivating genes encoding pro-apoptotic 
and/or negative regulators of cell cycle progression [10]. Additionally, a direct apoptotic role of the 
p53 protein at the mitochondrial compartment in response to genotoxic stress has been amply 
demonstrated [11, 12]. Mitochondrial p53 participates in the intrinsic apoptosis pathway by 
interacting with members of the Bcl-2 family to induce mitochondrial outer membrane 
permeabilization, thereby triggering the release of pro-apoptotic factors from the mitochondrial 
intermembrane space [13, 14]. p53 turnover is regulated by Mdm2, which binds p53 and functions 
as an ubiquitin E3 ligase to promote its degradation by the proteasome [15, 16]. It mediates both 
poly- and mono-ubiquitylation of p53, and while abundant levels of Mdm2 promote p53 poly-
ubiquitylation and degradation, limiting levels of Mdm2 promote p53 mono-ubiquitylation on one 
or few lysines [17]. 
ATM and NBS1 proteins are key regulators of the DNA damage response. ATM is a central 
component of the signal transduction pathway activated by DNA double-strand breaks (DSBs), and 
synchronizes DNA repair with the induction of p53-dependent apoptosis [4, 18]. Individuals who 
inherit germline ATM mutations on both alleles develop AT, a disorder characterised by 
progressive neurodegeneration and predisposition to the development of lymphoid malignancies 
[19, 20]. The cellular consequences of ATM dysfunction include chromosomal radiosensitivity, 
radioresistant DNA synthesis, loss of cell cycle checkpoints, and p53 dysfunction [18]. NBS1 acts 
by forming a complex with RAD50/MRE11 and by activating ATM. It is mutated in the NBS and 
cell lines derived from NBS patients display hypersensitivity to ionizing radiation (IR), 
chromosome instability, and defects in cell cycle checkpoint following DNA damage [20, 21]. The 
direct interconnection of ATM and NBS1, e.g. ATM phosphorylates NBS1 and NBS1 in turn is 
required for full ATM activation [22-24] accounts for the common pathogenetic mechanisms and 
the similar cellular and clinical phenotype of AT and NBS [20, 25, 26]. 
ActD is an anti-tumour antibiotic used in many chemotherapeutic protocols [27-29]. It intercalates 
into DNA and interferes with RNA polymerases and DNA topoisomerases, thus inhibiting 
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transcription and inducing various types of DNA damage [30-32], including DSBs [1]. This 
multiplicity of action is shared with many other genotoxic agents such as cisplatin and the 
topoisomerase I inhibitor camptothecin [33-35].  
We have previously reported a defective p53 accumulation following IR in AT and NBS cells [36-
39] and, like others, foud that DSBs in these cells are not completely repaired [1, 40]. Nevertheless, 
these residual DSBs did not induce apoptosis in patients’s quiescent cells, as also confirmed by our 
ongoing studies on genomic stability in T cells. Thus, the mechanism of radiation induced response 
is well defined in patients’ cells [41] at least to the point of accounting for the radiosensitivity of 
proliferating cells vs the characteristic radioresistence of quiescent cells. In contrast, we have shown 
that ActD treatment induces an accumulation of unrepairable DSBs and high amounts of total p53, 
followed by apoptosis in normal T-cells but not T cells from AT and NBS patients were resistant 
[1]. In this case, both the mechanism of p53 activity after ActD treatment and the underlying 
resistance of AT and NBS cells are still unknown. 
Here we show that ActD-induced apoptosis depends on a mitochondrial p53-dependent pathway 
and Bax activation, and demonstrate for the first time that AT and NBS T-cells are characterised by 
almost undetectable mitochondrial p53 accumulation, an altered p53 ubiquitination pattern and 
increased Mdm2 accumulation. These findings open new perspectives in understanding the 
multifaceted function of ATM and NBS1 in regulating apoptotic pathways.  
 
2. Material and methods 
2.1 Cell isolation, cell culture and drug treatment  
Peripheral blood from four healthy donors, three AT and two NBS patients was collected after 
signed informed consent. AT patients were either homozygous or compound heterozygous for 
truncating mutations; NBS patients were homozygous for the common 657del5 mutation. PBMC 
were isolated and T-cell lines, generated as described [42], were maintained by periodic stimulation 
with PHA (Gibco-Invitrogen, Paisley, UK) and irradiated allogeneic PBMC in complete RPMI 
medium (RPMI 1640 added with 1% Kanamycin, 1% Sodium Piruvate, 1% L-Glutamine, 1% non 
essential amino acids, 0.1% β-mercapto-ethanol) (all from Gibco-Invitrogen), supplemented with 
5% human serum (BioWitthaker, Cambrex, Baltimore, MD, USA) and 200 U/ml recombinant IL2 
(from the myeloma producing cell line IL2-t6, kindly provided by Dr A. Lanzavecchia, IRB, 
Bellinzona, Switzerland). All experiments were conducted on resting T cells (>95% in G0/G1). The 
Jurkat human leukemia cell line was purchased from the American Type Culture Collection 
(Rockville, MD, USA), and grown in complete RPMI medium supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Invitrogen). ActD was supplied by Sigma–Aldrich Co. (St. 
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Luis, MO, USA) and used at doses ranging from 0.05 to 0.5 µg/ml. Cultured T cells were γ-
irradiated (2 Gy) using a 6 MV accelerator (Elekta) at a dose of 2 Gy/min. α-pifithrin (α-PFT) and 
µ-pifithrin (µ-PFT) (Sigma-Aldrich Co.) were used at 30 µM and 10 µM respectively, and added 20 
minutes before ActD. Leptomycin B (LMB) (Applichem, Germany) was used at 10 nM and added 
30 minutes before ActD.  
 
2.2 Flow cytometry  
Cell viability was determined by propidium iodide (PI) (Sigma-Aldrich Co.) staining; PI was used 
at the final concentration of 1 µg/ml and maintained at room temperature for 15 min in the dark 
before the analysis. Cell survival was expressed after normalization to medium alone or 
supplemented with the drug's solvent (DMSO). Apoptosis was defined through double staining with 
anti-annexinV-FITC (BD PharMingen, San Diego, CA, USA) and PI, in accordance with the 
manufacturer’s instructions. Caspase activation was analyzed with anti-Active Caspase-3 (BD 
PharMingen) as primary antibody and a PE-conjugated goat anti-rabbit (BD PharMingen) as 
secondary antibody, using the Cytofix/Cytoperm Kit (BD PharMingen). Stained cells were analysed 
on a FACScan (Becton Dikinson & Co., San Jose CA, USA). Statistical analysis of cell survival 
and caspase-3 activation was performed with either the test of independence or the Student’s t-test. 
The significance were expressed in the figures with the asterisks: * p<0.05; **p<0.01; ***p<0.005.  
 
 
2.3 Gene silencing by siRNA 
The Amaxa Nucleofector system (Lonza, Cologne, Germany) and Amaxa Human T-cell 
Nucleofector kit were used for electroporation. Briefly, T-cells were resuspended in Nucleofector 
Solution, Scramble (ON-TARGET Non targeting pool, Thermo Scientific, Rockford, IL, USA ) or 
p53 specific (ON-TARGETplus SMART pool, Human TP53, Thermo Scientific) siRNA oligos 
(30pmol) were added to 6x106 T-cells/100 µL transfection buffer and nucleofected using the Amaxa 
Nucleofector II Device and program V-024, according to the manufacturer’s instructions. 
Nucleofected T-cells were maintained in fresh medium for 48 hours, then either treated with ActD 
for 24 hours or left untreated. Treated and untreated cells were harvested at the same time point.  
 
2.4 Immunofluorescence  
Approximately 400,000 T-cells for each condition were collected, fixed with 4% paraformaldehyde, 
permeabilized with 0.5% Triton X-100, and blocked with 6% bovine serum albumin and 2.5% 
normal goat serum. They were stained with anti-p53 (clone DO1), anti-BAX (clone 2D2), anti-
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Mdm2 (clone H221) specific Abs (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and 
with Alexa 546-conjugated goat anti-mouse as secondary Ab (Molecular Probes, Invitrogen). Green 
Fluorescent Mitotraker (Molecular Probes, Invitrogen) was used at the final concentration of 
100nM. Stained cells were transferred to poly-L-lysine-coated coverslips and slides were mounted 
with Mowiol (Calbiochem, San Diego, CA, USA). Fluorescence images were obtained with a 510 
Carl Zeiss confocal laser microscope using a ×63 objective. Colocalization analyses were 
performed with LSM510 Image examiner software from Zeiss, selecting the cytosolic area of 20 
different cells for each condition, in two independent experiments. Fluorescence intensity analysis 
was performed with Image examiner software from Zeiss, selecting 20 different cells for each 
condition elaborated as arbitrary units/pixel. Statistical analysis of fluorescence intensity was 
performed with the Student’s t-test. The significance were expressed in the figure with the asterisks: 
* p<0.05; **p<0.01.  
 
 
2.5 Cell extracts and subcellular fractionation 
Cells were harvested and washed with PBS, pelleted, and lysed in Laemmli buffer (0.125 M Tris-
HCl [pH 6.8], 5% SDS) containing as inhibitors 1 mM phenylmethylsulfonyl fluoride, pepstatin (10 
µg/ml), aprotinin (100 KIU/ml), leupeptin (10 µg/ml) and 1 mM sodium orthovanadate (Na3VO4) 
(all from Calbiochem). Total lysates were boiled for 2 min, sonicated, and quantitated by the micro-
bicinchoninic acid method (Thermo Scientific). For nuclear protein isolation, cells were harvested 
and washed with PBS, pelleted and lysed in 10mM Hepes, 10mM KCl, 1,5mM MgCl2, 0.7% NP-40 
(all from Sigma-Aldrich) buffer containing protease inhibitors; subsequently, nuclear proteins were 
isolated with 20mM Hepes, 0.42 M NaCl, 1,5 mM MgCl2, 0.2 mM EDTA, 25% Glycerol (all from 
Sigma-Aldrich) buffer containing protease inhibitors and quantitated by the micro-bicinchoninic 
acid method (Thermo Scientific) before analysis by immunoblotting. For subcellular fractionation, 
2x107 T-cells were harvested and washed with PBS; mitochondrial and cytosolic fractions were 
isolated with the use of the Mitochondria Isolation Kit for cultured cells (Thermo Scientific, 
reagent-based method). The mitochondrial pellet was lysed in Laemmli buffer, and the cytosolic 
supernatant was concentrated with a Microcon device (size cut-off 10 kDa) (Millipore Corporation, 
Bedford, MA, USA). Both fractions were quantitated by the micro-bicinchoninic acid method 
(Thermo Scientific) before analysis by immunoblotting. 
 
2.6 Immunoblot analysis 
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40 µg of total lysates and 20 µg of nuclear, mitochondrial and cytosolic fractions were size 
fractionated by SDS-PAGE 7 to 10% gels and electroblotted onto polyvinylidene difluoride 
membranes (Amersham, GE Healthcare, Buckinghamshhire, UK). After blocking with 5% nonfat 
dried milk in PBS plus 0.1% Tween (Sigma-Aldrich Co.), the membranes were incubated with anti -
p53 (clone DO7) (YLEM, Avezzano, Italy) , -Tom40 (H-300), -lamin A (H-102), -Mdm2 (H-221) 
(Santa Cruz Biotechnology), -vinculin (clone hVIN-1), -β-actin (clone AC-72) (Sigma-Aldrich Co.) 
specific Abs, and subsequently with peroxidase-conjugated secondary antibodies (Amersham, GE 
Healthcare). The immunoreactive bands were visualized by ECL Super Signal (Thermo Scientific) 
on autoradiographic films. Autoradiographic bands were scanned and quantified by Kodak 1D 
Image Analysis Software. p53 mono-ubiquitination was assessed through long exposures of p53 
immunoblots to evaluate the appearance of a signal in the range between 60kDa (one p53 
monoubiquitylated site) and 120kDa (all eight p53 monoubiquitylated sites), as described [17, 43]. 
 
3 Results 
3.1. T-cells from AT and NBS patients are resistant to a non-redundant p53-dependent apoptotic 
pathway induced by ActD 
To clarify the mechanism that makes AT and NBS T-cells resistant to ActD-induced apoptosis, we 
explored the death events initiated by ActD. Control cells harvested 15 hr after ActD treatment did 
not display any appreciable signs of apoptosis (data not shown), whereas after 24 hr there was an 
evident increase in the fraction of active caspase-3-positive and annexin V-positive/PI-negative, i.e. 
early apoptotic, cells (Fig. 1A and 1B). By contrast, similarly treated AT and NBS T-cells 
completely lacked caspase-3 activation, and were defective in phosphatidylserine translocation from 
the inner to the outer leaflet of the membrane (Fig. 1A and 1B). 
As in our previous study [1], control T-cells treated with ActD accumulated high amounts of total 
p53 (Fig. 1C). To determine whether p53 contributed to the stress response elicited by ActD, we 
examined the response of the p53-null Jurkat T-cell line [44]. Our western blot analysis confirmed 
that p53 was not expressed in Jurkat cells, even after ActD treatment (Fig. 1C). As shown in figure 
1D, they were resistant to ActD-induced apoptosis. Their viability at 72h was more than 60% 
(Jurkat versus control cells: p<0.0001 with the test of independence), similar to AT and NBS T-
cells [1], and were neither active caspase-3-positive nor AnnexinV-positive/PI-negative at 24 hr 
(Fig. 1A and B). As a second way to assess the p53 dependence of ActD-activated apoptotic 
pathway, we depleted p53 by siRNA in control T-cell lines. Immunoblot analysis confirmed that 
p53 levels decreased after p53 siRNA nucleofection (Fig 1E). We found that p53 knockdown 
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significantly increased survival (Fig.1F) and decreased caspase-3 activation (Fig 1G) following 
ActD treatment, further suggesting that p53 is required to activate ActD apoptotic pathway. 
These findings support the conclusion that ActD induces a p53-dependent apoptotic pathway in 
normal T-cells, and that the resistance of AT and NBS T-cells to ActD-induced apoptosis is due to 
its defective activation. 
 
3.2. Defective ActD-induced p53 cytoplasmic accumulation and Bax activation in AT and NBS T-
cells 
The similar apoptotic defects observed in AT and NBS T-cells and in p53-deficient Jurkat T-cells 
prompted us to look for defective p53 accumulation by AT and NBS T-cells following ActD 
treatment. Surprisingly, their total p53 protein level after 6 hr was only slightly reduced to 78% and 
98% of that in control T-cells in AT and NBS T-cells respectively (Fig. 2A), whereas p53 
accumulation induced by IR was clearly defective (about 10% and 28% that of control T-cells 
respectively), as assessed by both western blot analysis [36] and confocal microscopy (Figure 2D), 
as already reported [37-39]. 
We thus employed cell fractionation and immunoblot analysis in a more detailed search for major 
defects in p53 subcellular localization in control, AT and NBS T-cells 6 hours after ActD-treatment. 
The p53 detected in nuclear extracts from the patients was only slightly defective, being about 81% 
in AT and 77% in NBS cells compared to the controls (Fig. 2B). In addition, p53 was clearly visible 
in both the cytosol and the mitochondria of the controls, whereas its accumulation was highly 
defective in the cytosolic fraction of AT and NBS T-cells (about 20% in AT and 22% in NBS 
compared to the controls), and nearly undetectable in their mitochondrial fraction (about 6% in AT 
and 16% in NBS compared to the controls) (Fig. 2C).  
The distribution of p53 was then determined by immunfluorescence staining and confocal 
microscopy with a cytosolic probe (Mitotraker green) in conjunction with the anti-p53 antibody 
(red). In control T-cells p53 was not only present in the nucleus, but also in the cytosol 6 hr after 
ActD, as highlighted by the yellow signal in the double-staining with the cytosolic probe (Fig. 2D). 
In AT and NBS T-cells, on the contrary, p53 nuclear accumulation alone was evident at the same 
time point (Fig. 2D). Colocalization analysis confirmed these data: p53 was present in about 40% of 
the cytosolic area of ActD-treated normal T-cells, but in less than 5% of ActD-treated patients’ T-
cells (data not shown). After 2 Gy IR, a genotoxic stimulus that does not induce apoptosis in resting 
T-cells [1], p53 was exclusively nuclear in both control and patients’ T-cells (Fig. 2D). 
Cytosolic accumulation of p53 directly activates Bax to insert and oligomerize into the 
mitochondrial membrane, thus leading to the cascade of mitochondria-mediated apoptosis and 
 10
caspase-3 activation [13]. We therefore sought to find out whether high cytosolic p53 levels in 
ActD-treated cells were coupled with Bax activation. We monitored Bax distribution by 
immunofluorescence and confocal microscopy at 9-15-24 hours. In the control T-cells, Bax’s 
baseline cytosolic distribution remained until 15 hr after ActD, when a dot-like pattern was 
displayed by about 30% of these cells; this value increased to 35% at 24 hr, concomitant with the 
beginning of apoptosis (Fig. 2E and data not shown). When treated AT cells were examined, no 
changes in this baseline distribution were detected. In NBS cells, Bax was activated at significantly 
lower levels than in the controls (6% of positive cells at 24 hr) (Fig. 2E). 
These results suggested that cytoplasmic p53 accumulation and changes in Bax distribution are 
involved in ActD-induced apoptosis, and that this extra-nuclear accumulation and Bax activation 
are defective in AT cells and, to a lesser extent, in NBS cells.  
 
3.3. ActD-induced apoptosis is dependent on the mitochondrial targeting of p53 from an 
extranuclear pool  
To clarify the role of p53 in ActD-induced apoptosis, we used pharmacological manipulations to 
distinguish its nuclear and mitochondrial functions. Control T-cells were preincubated with two p53 
inhibitors that act through different mechanisms: α-pifithrin (α-PFT) reversibly blocks the p53-
mediated transactivation of p53-dependent responsive genes [45]; µ-PFT blocks the interaction of 
p53 with Bcl-xL and Bcl-2, and selectively inhibits p53 translocation to the mitochondria, without 
affecting its genomic transactivation function [46]. 
We used 0.5 µg/ml ActD in order to detect any effect of PFT within 24 hr. At longer incubation 
times, the activity of α-PFT and µ-PFT is partially lost (our data not shown). While the viability 
level of ActD-treated control T-cells did not change in the presence of α-PFT, preincubation with 
µ-PFT conferred significant resistance to ActD-induced apoptosis (70% viability at 24 hr) (Fig. 
3A). To demonstrate that blockage of mitochondrial p53 increases viability by inhibiting apoptosis, 
we assessed caspase-3 activation in control T-cells treated with ActD, either alone or in the 
presence of α-PFT or µ-PFT. µ-PFT preincubation reduced caspase-3 activation by about 86% 
compared to ActD alone (Fig. 3B), whereas α-PFT treatment had no effect, as expected. These data 
suggested that ActD-induced apoptosis depends on mitochondrial p53 functions. 
To further investigate the origin of mitochondrial translocated p53, a still debated issue [43, 47], we 
assessed the effects on cell viability during nuclear export blockage induced by treating control T-
cells with leptomycin B (LMB), a potent inhibitor of CRM1-mediated p53 nuclear export [48]. 
ActD was again used at a dose of 0.5 µg/ml to detect any effect of LMB within 24 hr since it is 
toxic at longer incubation times (our data not shown). The viability and caspase-3 activation of 
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these control T-cells did not change in the presence of LMB, suggesting that p53 does not need to 
traffic through the nucleus to activate the mitochondrial apoptosis (Fig 3C and 3D). To confirm 
these data, we performed immunoblot analysis of p53 accumulation and localization following 
ActD treatment in the presence of LMB. Cell fractionation experiments showed that cytoplasmic 
and nuclear p53 pools became independently stabilized upon stress (Fig. 3E). 
 
3.4. ActD-induced p53 mono-ubiquitination at multiple sites is defective in AT and NBS T 
lymphocytes. 
The nuclear versus cytoplasmic effect of p53 are determined by multiple post-translational 
modifications. Monoubiquitylation of p53 on one or few lysines is the preferred species that 
translocates to mitochondria in response to stress [17, 43]. We determined the ubiquitylation status 
of p53 in control, AT and NBS T-cells after ActD treatment. Long exposure of p53 immunoblot 
revealed an increase of (multi-)monoubiquitylated protein (6.7-fold at 9 hr) in the controls, whereas 
it was only about 1.4- and 2.9-fold at 9 hr in the AT and NBS cells respectively (Fig. 4A). Since the 
monoubiquitylated fraction is a function of the total accumulated protein, we normalised this 
monoubiquitylated p53 form on the total p53 protein level and found that whereas the 
monoubiquitylated fraction increased by 2.3-fold at 9 hr in the controls, it was only 0.35- and 0.71-
fold (i.e., it decreased with respect to total p53) in the AT and NBS cells respectively (data not 
shown). This defective ubiquitylation may explain the inability of AT and NBS T-cells to induce 
p53 mitochondrial localization. 
To demonstrate the importance of p53 mono-ubiquitination at multiple sites in directing p53 
mitochondrial localization, we determined its levels in the extranuclear compartments. Low levels 
in untreated cytoplasm increased significantly (2.5-fold) upon stress. Mono-ubiquitylated p53 was 
not found in untreated mitochondria, though some was detected following ActD treatment (Fig. 
4B). 
We then compared levels of Mdm2, the major E3 ubiquitin-protein ligase, following ActD and after 
2 Gy IR (Fig. 2D). In irradiated cells, Mdm2 upregulation occurred at high levels, whereas it was 
reduced in ActD-treated cells: compared to ActD-treated cells, 6 hours after IR Mdm2 increased by 
>2 fold (Fig. 4C). These differently induced levels may help to explain the different responses in 
ActD-treated and irradiated cells, as the low Mdm2 level we observed after ActD could favour p53 
mono-ubiquitylation and extranuclear p53 activity. We finally analysed Mdm2 level following 
ActD in T-cells from AT and NBS patients. Compared to control T-cells, in AT and NBS T-cells 
the levels of Mdm2 increased 2.0- and 2.3-fold, respectively (Fig. 4D). Mdm2 expression was also 
analysed by immunfluorescence staining and confocal microscopy. In the control T-cells Mdm2 
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increment was scarce 6 hr after ActD (Fig. 4E), while conversely, in AT and NBS T-cells the 
Mdm2 increment was markedly higher at the same time point (Fig. 4E). These data help to explain 
the poor fraction of p53 mono-ubiquitination at multiple sites observed in AT and NBS cells.  
 
4 Discussion 
Our results disclose an undescribed defect in mitochondrial p53 accumulation in AT and NBS T-
cells that makes them resistant to apoptosis following ActD treatment. This common defect may 
depend on reciprocal post-translational regulation between ATM and NBS1 [4, 22-24, 49], and 
should be listed among the features of AT and NBS cells. Conferring apoptosis resistance, this 
defect is particularly significant as it may contribute to the genomic instability typical of AT and 
NBS cells. 
Although acute sensitivity to IR and radiomimetic chemicals is considered to be a generalised 
feature of AT and NBS T-cells, loss of ATM may correlate with tumor resistance to some forms of 
DNA-damaging chemotherapy (DNA cross-linking agent cisplatin, topoisomerase II inhibitor 
doxorubicin, fludarabine, cyclophosphamide, chlorambucil) [50, 51]. This chemoresistance 
phenotype has been postulated as due to prevention of efficient execution of a p53-dependent 
apoptotic response: in p53 proficient cells, suppression of ATM protected tumors from being killed 
by genotoxic agents [52]. Defective apoptosis following DNA damaging treatments was also 
observed in NBS cells, and apoptosis resistance could not be ascribed to differences in p53 
phosphorylation and/or stabilization [53]. ATM has also been shown to be the key to the cascade of 
regulation of p53-mediated neuronal apoptosis following DNA damage: in ATM knockout mice, 
developing neurons failed to undergo apoptosis following treatment with various genotoxic 
compounds [54-56] and ATM inactivation was antiapoptotic in differentiated neurons [57]. These 
data indicate that ATM (and NBS) functions as a molecular “binary switch” that channels the 
effects of p53 signaling toward apoptosis by controlling its nuclear and cytoplasmic actions. It is 
tempting to speculate that the defect in mitochondrial p53 accumulation we have now described 
here in AT and NBS T-cells following ActD treatment may help to explain some of the apoptotic 
defects previously observed in ATM- and NBS1-deficient cells. 
Analysis of p53 expression revealed that treatment with ActD induced high amounts of total p53 
and the finding that p53 deficient Jurkat T-cells, as well as p53-silenced normal T-cells, were 
resistant to ActD-induced apoptosis suggested that this pathway was non-redundant. Aside from 
nuclear stabilization, ActD caused cytoplasmic p53 accumulation and translocation to mitochondria. 
To ascertain the relative contribution of nuclear versus mitochondrial p53 to ActD-induced 
apoptosis, we employed two distinct variants of the chemical p53 inhibitor pifithrin. Pre-treatment 
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of T cells with µ-PFT markedly decreased ActD-induced caspase-3 activation, while inhibition of 
the transcriptional arm of p53 with α-PFT failed to protect T-cells from ActD-induced apoptosis. 
These results suggest that the extranuclear p53 pool may prevail over its nuclear counterpart in 
mediating cell death. Thus, the transcription independent p53 program was a major contributor to 
ActD-induced apoptosis in human T-cells and this could be partly explained by the transcriptional 
inhibitory activity of ActD, which would interfere with transactivating p53 activity. 
The origin of mitochondrial translocated p53 is still debated [43, 47]: monoubiquitination of p53 
exposes a C-terminal nuclear export sequence and promotes the dissociation of Mdm2, thereby 
allowing further post-translational modifications of the C-terminal lysines, such as sumoylation, 
which promote nuclear export of p53 [58]. Interestingly, however, stress-induced increases in 
cytoplasmic p53 have been primarily attributed to stabilization of existing cytoplasmic p53 pools 
instead of shuttling of nuclear p53 into the cytoplasm: careful fractionation experiments suggested 
that both nuclear and cytoplasmic p53 pools were stabilized independently [43, 59]. Using a non-
competitive nuclear export blockade (LMB), we found that nuclear p53 export was not required for 
mitochondrial translocation upon DNA damage. Instead, distinct nuclear and cytoplasmic p53 pools 
became simultaneously stabilized after ActD treatment. This is consistent with previous 
observations [13, 43], and indicates that mitochondrially translocated p53 arises from a distinct 
cytoplasmic pool. 
We have also described a role for Bax in the apoptotic pathway induced by ActD. ActD treatment 
was followed by an evident change in Bax distribution, while confocal microscopy illustrated the 
appearance of Bax aggregates reflecting Bax oligomerization and mitochondria pore formation [60]. 
Bax activation was not observed in AT and NBS cells. NBS1-deficient cells have been found to 
display a defective apoptosis following DNA damage that was not due to altered gene expression, 
but to a direct role of NBS1 in regulating apoptosis induction by stimulating Bax activation. The 
same defect was also described in cells expressing NBS1 with a mutation in the ATM 
phosphorylation sites [61]. 
How can ATM and NBS1 impact on extranuclear p53 accumulation? The nuclear versus 
cytoplasmic effects of p53 are determined by multiple post-translational modifications that affect its 
interaction with other proteins and its biological activities. One of the most substantial 
modifications is p53 monoubiquitylation, mainly mediated by low Mdm2 activity, that stimulates 
p53 arrival at the mitochondria; here, p53 is rapidly deubiquitylated by mitochondrial HAUSP, thus 
generating the apoptotically active non-ubiquitylated p53 [43, 59]. Consistent with a rapid p53 
deubiquitylation was our observation of more abundant mono-ubiquitylated p53 in the cytosolic 
than in the mitochondrial fractions of ActD-treated cells. The regulation of p53 ubiquitylation by 
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Mdm2 is a rather complex process and ATM has different roles in this process, direct and indirect. 
ATM directly phosphorylates Mdm2, decreasing its activity and stability of this protein [62, 63]; 
phosphorylation by ATM also inhibits Mdm2 RING domain oligomerization, and specifically 
suppresses its action on p53 polyubiquitylation [64]. In addition, ATM mediates indirect 
phosphorylation of Mdm2 via the c-Alb kinase, which reduces the Mdm2-mediated ubiquitylation 
[65]. Mdm2 activity is in turn regulated by Mdmx, promoting Mdm2’s activity as an E3 ligase of 
p53. ATM also phosphorylates Mdmx contributing to ubiquitylation and degradation of Mdmx 
[66]. Finally, ATM phosphorylation of Mdm2 and Mdmx decreases ubiquitin-specific protease 
HAUSP’s binding to Mdm2/MdmX, promoting their proteasomal degradation [67]. Alteration of 
any of these events could favour changes in the ubiquitylation pattern of p53. Indeed, our 
comparison of p53 ubiquitylation pattern in normal, AT and NBS T-cells following ActD treatment 
disclosed a reduced monoubiquitylated p53 fraction in patients’ T-cells. This confirms that 
monoubiquitylation of p53 is regulated by ATM and suggests for the first time that it is also 
regulated by NBS1, and contributes to the p53-mediated apoptotic pathway activated by ActD. 
Second, our finding that Mdm2 poorly accumulates in control T-cells treated with ActD treatment is 
consistent with a role for low Mdm2 level, through its promotion of p53 monoubiquitylation, in the 
apoptotic pathway thus induced. Third, the increased Mdm2 levels in ActD-treated AT and NBS T-
cells provide a mechanistic link to the apoptotic defect observed in patients’ T-cells, suggesting that 
altered Mdm2 regulation by ATM and, for the first time, by NBS1 is responsible for altered 
ubiquitylation of p53 in AT and NBS cells. It is notable that the amount of Mdm2 in ActD-treated 
patients’ T cells was comparable to that present in irradiated control T cells, where p53 accumulated 
only in the nucleus and no apoptotis occourred. 
Although other ubiquitin ligases, regulated directly or indirectly by ATM after DNA damage, have 
been involved in p53 regulation [68, 69], they are only capable of mediating its polyubiquitylation 
by addressing it to proteasome-mediated degradation. The only exception is represented by MLS2, 
a new E3 ligase described by Kruse and Gu [70], which regulates p53 subcellular localization by 
monoubiquitylation, without affecting p53 stability. The possibility that this ubiquitin ligase or 
additional p53 modification can also contribute to p53 localization and activity following ActD 
treatment cannot be ruled out at the moment. 
In conclusion, we provide new insights linking the pro-apoptotic activity of ActD with the 
mitochondrial translocation of p53 and dependence of this phenomenon on functional ATM and 
Nbs1. These data might help to explain some of the apoptotic defects previously observed in ATM- 





Figure 1: Selective resistance to ActD-induced apoptosis of T-cells from AT and NBS patients. 
(A) Cultured T-cells from one control, one AT and one NBS patient, and Jurkat T-cells were kept 
for 24 hr in medium alone or with 0.05 µg/ml ActD, then harvested and stained with anti-active 
caspase-3 antibody. Percentages of active caspase-3+ cells are indicated.  
(B) Cultured T-cells from one control, one AT and one NBS patient and Jurkat T-cells were kept for 
24 hr in medium alone or with 0.05 µg/ml ActD, then harvested and stained with anti-annexin V 
antibody and PI. Percentages of PI- annexin V+ cells are indicated. 
(C) Western blot analysis of p53 accumulation on control and Jurkat T-cells harvested before or at 
various times after 0.05 µg/ml ActD treatment. Probing for β-actin checked lanes for protein 
content. 
(D) Cultured T-cells from three controls () and Jurkat T-cells () were kept in medium alone or 
in medium containing 0.05 µg/ml of ActD, harvested at 24, 48 and 72 hr and analyzed by flow 
cytometry after staining with PI. Viability is shown as mean±SD of three independent experiments. 
(E) Western blot analysis of p53 in control T-cells transfected with either scrambled or p53 siRNA 
and treated for 24 hr with 0.05 µg/ml ActD. Probing for vinculin checked lanes for protein content. 
(F) Control T-cells transfected with either scrambled or p53 siRNA were treated with 0.05 µg/ml 
ActD and analyzed at 24 hr by PI staining. Data are normalized to survival in medium alone (bars, 
mean±SD of two independent experiments) 
(G) Control T-cells transfected with either scrambled or p53 siRNA were kept for 24 hr in medium 
alone or with 0.05 µg/ml ActD, harvested and stained with anti-active caspase-3 antibody. 
Percentages of active caspase-3+ cells are indicated. 
 
 
Figure 2: Defective ActD-induced p53 cytoplasmic accumulation and Bax activation in T-cells from 
AT and NBS patients. 
(A) Western blot analysis of p53 accumulation on control, AT and NBS T-cells harvested before or 
at various times after 0.05 µg/ml ActD treatment. Probing for β-actin checked lanes for protein 
content. 
(B) Immunoblotting analysis of nuclear fractions from control, AT and NBS T-cells harvested 
before (-) or 6 hr after 0.05 µg/ml ActD treatment (+). Probing for vinculin and lamin A checked 
lanes for protein content and purity of the fractions.  
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(C) Immunoblotting analysis of cytosolic and mitochondrial fractions from control, AT and NBS T- 
cells harvested before (-) or 6 hr after 0.05 µg/ml ActD treatment (+). Probing for vinculin and 
Tom40 checked lanes for protein content and purity of the fractions. One representative experiment 
out of two is shown.  
(D) Confocal analysis of p53 localization. T-cells from one donor, one AT and one NBS patient 
were harvested before or 6 hr after either 2Gy γ-IR or 0.05 µg/ml ActD and stained with anti-p53 
mAb as primary antibody, with Alexa 546-conjugated goat anti-mouse as secondary Ab and with 
Green Fluorescent Mitotraker. One representative experiment out of three is shown. 
(E) Confocal analysis of Bax distribution. Cultured T-cells from one donor, one AT and one NBS 
patient were harvested before or 15 hr after 0.05 µg/ml ActD and stained with anti-Bax mAb as 
primary antibody, with Alexa 546-conjugated goat anti-mouse as secondary Ab. One representative 
experiment out of two is shown. 
 
Figure 3: Effect of the p53-inhibitors α-PFT and µ-PFT, and of nuclear export blockage on the 
ActD-induced apoptosis. 
(A) T-cell lines from three healthy donors were treated with either 10µM µ-PFT or 30µM α-PFT 
alone or in conjunction with 0.5 µg/ml ActD, and analyzed at 24 hr by PI staining. Data are 
normalized to survival in medium alone (bars, mean±SD of three independent experiment) 
(B) T-cell lines from three healthy donors were treated with either 10µM µ-PFT or 30µM α-PFT 
alone or in conjunction with 0.5 µg/ml ActD, and analyzed at 24 hr with anti-active caspase-3 
antibody. Data are normalized to caspase activation with ActD alone (bars, mean±SD of three 
independent experiment) 
(C) T-cell lines from two healthy donors were treated with 10 nM LMB, alone or in conjunction 
with 0.5 µg/ml ActD, and analyzed at 24 hr by PI staining. Data are normalized to survival in 
medium alone (bars, mean±SD) 
(D) T-cell lines from two healthy donors were treated with either 10 nM LMB, alone or in 
conjunction with 0.5 µg/ml ActD, and analyzed at 24 hr with anti-active caspase-3 antibody. Data 
are normalized to caspase activation with ActD alone (bars, mean±SD) 
(E) Immunoblotting analysis of p53 accumulation in control T-cells in the presence of LMB. Left 
panel: T-cells were harvested before (-) or 6 hr after treatment with 0.05 µg/ml ActD, alone or in 
conjunction with 10 nM LMB, and then analysed for their total protein extract (left panel), nuclear 
fraction (central panel), and cytosolic and mitochondrial fraction (left panel). Probing for vinculin, 
lamin-A and Tom40 checked lanes for protein content and purity of the fractions. One 
representative experiment out of three is shown. 
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Figure 4: Defective p53 mono-ubiquitination at multiple sites in AT and NBS T-cells following ActD 
treatment.  
(A) Immunoblotting analysis of p53 mono-ubiquitination at multiple sites on total protein extract 
from control, AT and NBS T-cells harvested before or at various times after 0.05 µg/ml ActD 
treatment. Probing for vinculin checked lanes for protein content. Quantification of p53 mono-
ubiquitination at multiple sites is shown as normalized for vinculin content. 
(B) Immunoblotting analysis of p53 mono-ubiquitination at multiple sites of mitochondrial and 
cytosolic fractions from a control T-cell line harvested before (-) or 6 hr after 0.05 µg/ml ActD 
treatment (+). Probing for vinculin and Tom40 checked lanes for protein content and purity of the 
fractions. One representative experiment out of two is shown.  
(C) Time course analysis of Mdm2 levels on control T-cells harvested before or at various times 
after either 0.05 µg/ml ActD treatment or 2 Gy gamma irradiation. Probing for β-actin checked 
lanes for protein content. 
(D) Western blot analysis of Mdm2 from control, AT and NBS T-cells harvested before (-) or 6 
hours after 0.05 µg/ml ActD treatment (+). Probing for vinculin checked lanes for protein content. 
Quantification of Mdm2 signal is shown after normalization for vinculin content. 
(E) Confocal analysis of Mdm2 levels following ActD treatment. Upper panel: normal, AT and 
NBS T-cells were harvested before or 6 hr after 0.05 µg/ml ActD treatment and stained with anti-
Mdm2 mAb as primary antibody, with Alexa 546-conjugated goat anti-mouse as secondary Ab. A 
representative experiment out of three is shown. Lower panel: quantification of Mdm2 levels before 
(-) or 6 hr after 0.05 µg/ml ActD (+) on two control, three AT and two NBS T-cells is shown. 
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